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Background: Choroidal neovascularization (CNV) is a rare complication of intermediate uveitis. Risk factors are not
well-characterized. Here, we describe a case of peripapillary CNV in a patient with intermediate uveitis and explore
the pathophysiology and treatment of this condition. This study is a case report and review of the literature.
Results: A 15-year-old boy with intermediate uveitis - suppressed for the preceding year on immunosuppressive
therapy and low-dose corticosteroids - and chronic disc swelling presented with unilateral metamorphopsia,
peripapillary subretinal hemorrhage, and subretinal fluid. Fluorescein angiogram confirmed the presence of an
active choroidal neovascular membrane. Treatment with intravitreal bevacizumab 1.25 mg every 4 weeks for 4
months resulted in resolution of subretinal fluid, subretinal hemorrhage, and regression of the CNV. The patient's
intermediate uveitis remained inactive throughout this time.
Conclusion: Review of the existing literature and pathophysiologic consideration suggests that chronic disc edema
may be a risk factor for this condition. Peripapillary CNV in the context of intermediate uveitis appears to respond
well to VEGF-inhibitor therapy.
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Background
Choroidal neovascularization (CNV) occurs rarely in the
context of intermediate uveitis [1]. Only three such cases
have previously been reported in the English literature,
two of which presented in a peripapillary location [1,2].
In the Systemic Immunosuppressive Therapy for Eye
Diseases (SITE) Cohort Study, representing the experi-
ence of five US tertiary uveitis centers including ours, 0/
1,978 patients with intermediate uveitis presented with
peripapillary CNV (upper limit of a one-sided 97.5%
confidence interval = 0.19%). Here, we report a case of
peripapillary CNV in a patient with intermediate uveitis
and explore the pathophysiology and outcome of this
condition. The project was conducted in accordance
with the principles of the Declaration of Helsinki, with* Correspondence: john.kempen@uphs.upenn.edu
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of the University of Pennsylvania.
Case report
After completion of the SITE Cohort Study at our center,
a 15-year-old male presented to our institution with blurry
vision in the inferotemporal quadrant of the left eye for 1
day, which upon further questioning represented meta-
morphopsia. The patient denied redness, eye pain, light
sensitivity, or floaters. The patient had longstanding inter-
mediate uveitis and chronic disc swelling, which we
observed to be suppressed for the past year. At the time of
presentation with metamorphopsia, the patient was taking
mycophenolate mofetil 1 g twice daily, methotrexate 25
mg once weekly, and folic acid 1 mg daily. He was other-
wise healthy, and past medical history was unremarkable.
Previous laboratory workup for conditions associated with
intermediate uveitis was negative.
The patient's best corrected visual acuity was 20/20 in
both eyes. Pupils, intraocular pressures, and color vision
were normal. No afferent pupillary defect was present.
Visual field was full in the right eye and showed an infero-
temporal defect in the left eye. Slit lamp biomicroscopyan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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cells or flare. Fundus examination of the right eye showed
stable chronic disc swelling but was otherwise unremark-
able. In addition to disc swelling, the left eye fundus
showed peripapillary subretinal hemorrhage and subret-
inal fluid extending into the macula (Figure 1a,b). Fluores-
cein angiogram showed an active choroidal neovascular
membrane adjacent to the disc in the left eye (Figure 1c,
d). There was no evidence of cystoid macular edema, per-
iphlebitis, snowballs, or snowbanking in either eye on clin-
ical exam, optical coherence tomography (OCT), and
fluorescein angiogram. B-scan ultrasound showed bilateral
disc elevation with fluid and positive 30° sign. Echography
showed no evidence of optic disc drusen. MRI of the brain
and orbits was normal; lumbar puncture revealed an
opening pressure of 180 mm H2O at the upper limit of
normal range.
The patient was treated with intravitreal bevacizumab
1.25 mg every 4 weeks for 4 months and retrobulbar
triamcinolone acetonide 40 mg once at 6 weeks after pres-
entation with the CNV. Acetazolamide 500 mg twice daily
for several weeks after presentation did not decrease the
disc swelling, at which point acetazolamide was discontin-
ued. At 8 months follow-up, the patient's vision was stable
and exam showed resolution of subretinal hemorrhage
and fluid (Figure 2a,b) but continued traction lines in the
area of the affected retina. Because the disc swelling grad-
ually resolved over several months of follow-up, no further
lumbar punctures were obtained.
Throughout this time, the patient's intermediate uve-
itis remained inactive. He was maintained on mycophe-
nolate mofetil 1 g twice daily and methotrexate 25 mg
once weekly. He was followed-up at our institution regu-
larly over the next 3 years and did well. At last follow-
up, the uveitis was inactive; no recurrence of CNV or
disc swelling was noted throughout this period. His
complaints of metamorphopsia gradually subsided, but
he is still aware of metamorphopsia when he covers the
right eye corresponding to the still-persistent traction
lines in the nasal macula. It remains unclear whether the
etiology of the disc swelling was from slowly resolving
inflammatory disc edema, corticosteroid-induced intra-
cranial hypertension, or both.
Discussion
Most cases of CNV in uveitis occur in posterior uveitis
or panuveitis. CNV in intermediate uveitis is rare with
only three cases reported in the literature; two of the
three cases were noted to occur adjacent to the disc
(Table 1) [1,2]. Arkfeld and Brockhurst reported the first
of these cases in a 29-year-old female with sarcoid-
related bilateral intermediate uveitis [2]. The patient had
disc swelling and active intermediate uveitis in the
involved eye which was treated with oral prednisone.The disc swelling occurred in the involved eye 10
months prior to the onset of peripapillary CNV. She was
treated with argon green laser photocoagulation and did
well with CNV regression and significant visual im-
provement. Garcia et al. reported the second case of a
15-year-old female who presented with intermediate
uveitis, vasculitis, papillitis, and peripapillary CNV [1].
The patient was treated with systemic corticosteroids
and one dose of intravitreal bevacizumab 1.25 mg. On
follow-up 7 months later, vision improved significantly,
vasculitis resolved, and CNV regressed. Garcia et al.
reported another case of a 27-year-old female with
bilateral intermediate uveitis and chronic cystoid macu-
lar edema in the right eye [1]. Systemic workup for con-
ditions associated with intermediate uveitis including
sarcoidosis evaluation was negative. The patient was
noncompliant with the treatment and presented 1 year
after a flare-up with decreased vision and a subfoveal
pigmented granuloma in the right eye which the authors
described as regressed CNV.
Histopathologic studies have provided insight into the
potential mechanisms in the development of peripapil-
lary CNV [3]. Sarks provided clinicopathologic correl-
ation of 21 eyes with peripapillary CNV from AMD [3].
Based on histopathologic evidence, Sarks hypothesized
that peripapillary CNV originates either from the chor-
oidal vessels passing around the termination of Bruch's
membrane or from the choroidal vessels passing through
defects in Bruch's membrane. In the above reported
cases of peripapillary CNV in intermediate uveitis, it is
interesting to note that chronic disc edema was present
prior to the onset of all cases. Arkfeld and Brockhurst
hypothesized that chronic disc swelling may increase the
potential space between Bruch's membrane and swollen
disc tissue facilitating ingrowth of choroidal vessels
around the termination of Bruch's membrane [2]. Alter-
natively, chronic disc swelling may result in the deform-
ation of the peripapillary Bruch's membrane leading to
breaks in Bruch's membrane facilitating ingrowth of the
choroidal neovascular tissue under the RPE [4]. Peripa-
pillary CNV has also been observed in conditions caus-
ing chronic disc swelling such as idiopathic intracranial
hypertension and hydrocephalus [5-8].
Peripapillary CNV is characterized clinically by the
presence of a choroidal neovascular membrane adjacent
to the disc producing subretinal hemorrhage, fluid, and/
or exudate [4]. OCT characteristics suggestive of CNV
include the presence of subretinal fluid, subretinal
hemorrhage, subretinal hyperreflective lesion, and intrar-
etinal fluid. On fluorescein angiogram, well-defined
CNV appears as a lacy network of capillary plexuses
with leakage as the angiogram progresses [9]. Occult
CNV can appear as an area of stippled hyperfluo-
rescence on angiogram. The choroidal neovascular
Figure 1 Color fundus photograph, optical coherence tomography, and fluorescein angiogram at presentation. (a) Color fundus
photograph of the left eye at presentation demonstrating disc swelling with peripapillary subretinal hemorrhage and subretinal fluid. (b)
Intraretinal and subretinal fluid temporal to the disc is evident on optical coherence tomography. (c) Early and (d) late fluorescein angiograms of
the left eye reveals a choroidal neovascular membrane adjacent to the disc.
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Figure 2 Color fundus photograph and optical coherence
tomography at follow-up. (a) Color fundus photograph of the left
eye 8 months after presentation showing resolution of the
subretinal fluid and hemorrhage. (b) The subretinal fluid has
resolved on optical coherence tomography.
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hyperplasia, fibrous tissue, or serous pigment epithelial
detachment [9].
Peripapillary CNV has certain unique features com-
pared to its macular counterpart. First, peripapillary
CNV is associated not just with diseases affecting chor-
ioretinal tissue adjacent to the disc but also with diseases
affecting the optic nerve head. For example, peripapillary
CNV can be seen in optic disc drusen, congenital disc
anomalies, tilted disc, and disc swelling [4]. Second, peri-
papillary CNV may develop from the breakthrough of
abnormal choroidal blood vessels through Bruch's mem-
brane in addition to growth of vessels around the ter-
mination of Bruch's membrane [2-4]. Third, the
occurrence of clinical symptoms prior to the extension
of the lesion into the fovea may allow detection and
treatment of these lesions with potentially more favor-
able visual outcomes compared to their foveal counter-
parts [4].
Several treatment options exist for peripapillary CNV in
uveitis including vascular endothelial growth factor inhibi-
tors, argon laser photocoagulation, and photodynamic
therapy [10-13]. In the above cases, all patients underwent
treatment with either argon laser photocoagulation or
intravitreal bevacizumab (as used in our case) and did well
with significant improvements in vision and CNV regres-
sion. For lesions adjacent to vital structures such as the
optic disc, therapy with bevacizumab injection likely is
safer than laser photocoagulation or photodynamic ther-
apy and is reasonably cost-effective.
In conclusion, patients with intermediate uveitis and
chronic disc swelling may be at risk for peripapillary
CNV. Control of inflammation without the use of corti-
costeroids likely will improve disc swelling in most cases,
even though resolution of disc swelling may be delayed
in some instances, as in our case. Corticosteroid-
induced or idiopathic intracranial hypertension should
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active inflammation. Chronic disc swelling should be
resolved if possible to avoid complications. CNV has
been reported to develop during times of quiescence or
active inflammation [1,2]. Management with a vascular
endothelial growth factor inhibitor likely is the treatment
of choice, along with control of inflammation and con-
trol of any associated factors that may be present such
as intracranial hypertension [13]. Based on the limited
number of observations available, the prognosis of this
condition with appropriate treatment appears favorable.
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